Our study suggests that the ability to generate an adequate immune response is vital for the disease course of COVID-19, as our data revealed that while not statistically significant, there did appear to be a slight trend toward worse outcomes for patients who received lympho-depleting chemotherapy within 30 days of their diagnosis versus patients who did not receive lympho-depleting chemotherapy within 30 days of their diagnosis.
← all excerpts
High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies.
1
—
—